Side by side, hype turned down
Compare peptide evidence—not the marketing.
These guides group commonly searched peptides without pretending they are interchangeable or naming a universal “best.”
GLP-1 peptides compared in plain English
How semaglutide, tirzepatide, liraglutide, and investigational retatrutide differ in targets, evidence, and approval status.
Status + evidence + uncertainty
Peptides for weight management: approved versus experimental
A status-first look at approved medicines and experimental peptides discussed for body weight.
Status + evidence + uncertainty
Peptides for recovery: what evidence exists?
What the evidence really says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.
Status + evidence + uncertainty
Peptides for skin and aging: research versus hype
A careful guide to peptide research, cosmetic ingredients, injectable claims, and the slippery word “anti-aging.”
Status + evidence + uncertainty
Growth hormone pathway peptides: what readers should understand
How tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.
Status + evidence + uncertainty
Mitochondrial peptides compared: medicine versus early biology
How FDA-approved elamipretide differs from preclinical MOTS-c and Humanin research in status, evidence, muscle claims, and healthy-aging hype.
Status + evidence + uncertainty
Peptides for cognition and brain research: evidence versus nootropic claims
A status-first comparison of Semax, Selank, oxytocin, and Humanin for cognition, social functioning, anxiety, and neuroprotection.
Status + evidence + uncertainty
Peptides for muscle growth and performance: what human evidence shows
Why growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.
Status + evidence + uncertainty
Next-generation metabolic peptides: beyond GLP-1 alone
How amylin analogs and glucagon-containing co-agonists differ in targets, trial maturity, liver research, weight evidence, and FDA status.
Status + evidence + uncertainty
Gut-signaling peptide medicines: three very different uses
Why linaclotide, plecanatide, and teduglutide are all gut-related peptides but are not interchangeable treatments or evidence for general gut repair.
Status + evidence + uncertainty
GLP-1 peptides in Parkinson research: one signal, one failed confirmation
What the positive LIXIPARK trial and negative exenatide Phase 3 study say about GLP-1 neuroprotection claims.
Status + evidence + uncertainty